The short buyer list in veterinary biologics

Exit analysis comes first in this division, and in veterinary biologics the exit is a list of names. A producer holding thirty to eighty product registrations across two or three species will be bought by a larger producer seeking those registrations, by a generalist animal-health group building a species franchise, or by a private owner with a longer horizon than ours. Across the markets our desk covers, that list rarely exceeds six parties. Everything downstream of the purchase price follows from the length of the list.

A short buyer list changes the arithmetic in two directions. It caps the multiple, because no auction is competitive when the bidders know each other and know what each already owns. It also protects the floor, because the assets are registrations that cannot be built quickly and the buyers cannot manufacture time. The firm underwrites to the floor. We assume one credible bidder at exit, price the position on that assumption, and treat any second bidder as a return we did not need.

The improvement plan therefore has to be legible to the specific buyer we expect. A producer that wants a species franchise pays for registrations in that species and discounts everything else. A producer that wants a plant pays for capacity and inspection history and treats the product range as an obligation. Our operating partners write the plan around one of those two buyers before completion, not after. Where the plan cannot be written, the position does not clear the firm's first test and we do not proceed.

Hold periods in the sector run longer than the divisional average. A registration transfer, a plant review and two clean batch-release cycles take between eighteen and thirty months in most jurisdictions where the firm holds positions. Adding a second country to the dossier adds another two years. Our animal-health commitments are written on a five to seven year horizon, and the facilities that support them are sized so that no realisation is forced by a funding date rather than by the calendar of the asset.

Regulation sets that calendar and does not negotiate. Every jurisdiction we work in requires a marketing authorisation per product and per species, a licensed manufacturing site, and a batch-release routine subject to inspection. The supervisory authority reviews a change of control and may re-inspect. None of this is unusual and none of it is fast. The barrier it creates is the reason the sector is worth entering, and the reason a buyer will pay for a dossier that is already assembled and already current.

Capital earned here does not stay here. The firm's first two animal-health positions were funded from the founding partnership's own balance sheet in 2019 and 2020, and the proceeds of the first realisation are committed to information infrastructure rather than to a third veterinary producer. The discipline is deliberate. A sector with six buyers is a good place to originate and a poor place to compound, because the same short list that protects the floor also limits what a second position can be sold for.

Published 2021-01-21 by the Private Equity division. Research is prepared for eligible counterparties and does not constitute advice.